Shots:

• Merus to receive $40M up front- $20M as an equity investment- ~$540M as development & commercial milestones making it a total of $1.6B for three products- along with royalties- following the commercialization of therapies
• Merus will lead discovery and early-stage research activities while Loxo Oncology at Lilly will be responsible for additional research- development- and commercialization activities
• The collaboration leverages Merus' Biclonics platform along with the scientific & rational drug design expertise of Loxo Oncology at Lilly to research and develop up to three CD3-engaging T-cell redirecting bispecific Ab therapies

 ­ Ref: PRNewswire | Image: Lilly